HC Wainwright Has Positive Opinion of Nkarta FY2026 Earnings

Key Points

• HC Wainwright maintained its Buy rating and nudged its FY2026 EPS estimate to a loss of $1.84 per share, from a projected loss of $1.86. It forecast narrowing losses through FY2030.
• Nkarta reported a quarterly loss of $0.45 per share, missing analysts’ consensus estimate of a $0.40 loss.
• The company reported preliminary clinical responses and safety findings for its NKX019 therapy in trials for myositis and systemic sclerosis; the results are early. Analyst coverage overall is “Moderate Buy,” with an average price target of $11.20.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - HC Wainwright upped their FY2026 earnings per share estimates for shares of Nkarta in a research note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will earn ($1.84) per share for the year, up from their prior estimate of ($1.86). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Nkarta's FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at ($0.74) EPS and FY2030 earnings at ($0.60) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.05).

A number of other equities analysts have also recently weighed in on NKTX. Weiss Ratings restated a "sell (d-)" rating on shares of Nkarta in a research report on Monday, September 21st. Needham & Company LLC reiterated a "buy" rating on shares of Nkarta in a research report on Monday. Stifel Nicolaus dropped their price target on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Finally, Wall Street Zen downgraded Nkarta from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.20.

Nkarta Price Performance

Nkarta stock opened at $1.59 on Tuesday. The stock has a market capitalization of $113.88 million, a PE ratio of -0.92 and a beta of 1.24. Nkarta has a 12 month low of $1.13 and a 12 month high of $3.72. The business has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $2.51.

Institutional Trading of Nkarta

Several large investors have recently bought and sold shares of NKTX. BlackRock Inc. acquired a new stake in Nkarta in the 2nd quarter valued at about $17,830,000. Monaco Asset Management SAM acquired a new position in shares of Nkarta during the 2nd quarter worth approximately $6,717,000. Renaissance Technologies LLC boosted its holdings in shares of Nkarta by 1.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company's stock worth $3,655,000 after purchasing an additional 30,350 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Nkarta in the second quarter valued at approximately $2,564,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Nkarta by 74.4% in the first quarter. Dimensional Fund Advisors LP now owns 346,593 shares of the company's stock valued at $731,000 after purchasing an additional 147,894 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company's stock.

Key Stories Impacting Nkarta

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Nkarta reported initial clinical responses and safety findings for NKX019 in trials for myositis and systemic sclerosis. Early data may support the therapy’s potential, though the results are preliminary. Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
• Positive Sentiment: HC Wainwright raised its earnings-per-share estimates for 2027–2030, projecting smaller losses than previously expected, and maintained its Buy rating. Its 2026 estimate improved only slightly. Nkarta discusses initial NKX019 clinical data
• Positive Sentiment: Needham reaffirmed its Buy rating, adding to the supportive analyst commentary. Needham rating information

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta's research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.